Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Stem Cell Therapy - A Solution for Parkinson's disease


News provided by

StemGenex

Oct 23, 2013, 10:35 ET

Share this article

Share toX

Share this article

Share toX

LA JOLLA, Calif., Oct. 23, 2013 /PRNewswire/ -- "Stem cell therapy is an enthralling new achievement for the management of Parkinson's disease," said Dr. Stacy, the Vice Dean for Clinical Research, Neurology at Duke University School of Medicine.

According to the Michael J. Fox Foundation, Parkinson's disease in the U.S. alone affects one in 100 people over 60 and 60,000 new cases will be diagnosed this year. Additionally, today's best Parkinson's drug was discovered in 1967.

Continue Reading
Adipose-derived adult stem (ADAS) cells are the multipotent cells and precursors for the important cells of the central nervous system. Researchers have found that these stem cells self-renew and provide a therapeutic effect by differentiating into dopaminergic neurons and expressing neurotrophic factors e.g. brain-derived neurotrophic factor (BDNF) and glial derived neurotrophic factor (GDNF). All these facilitate protection of the nigrostriatal system thus offering a revolutionary and new prospect for the treatment of Parkinson's disease, particularly in cases where dopamine-replacement approaches remain unsuccessful to satisfactorily combat the symptoms. (PD is the result of loss of dopamine-generating cells in the nigrostriatal system). (PRNewsFoto/StemGenex) (PRNewsFoto/STEMGENEX)
Adipose-derived adult stem (ADAS) cells are the multipotent cells and precursors for the important cells of the central nervous system. Researchers have found that these stem cells self-renew and provide a therapeutic effect by differentiating into dopaminergic neurons and expressing neurotrophic factors e.g. brain-derived neurotrophic factor (BDNF) and glial derived neurotrophic factor (GDNF). All these facilitate protection of the nigrostriatal system thus offering a revolutionary and new prospect for the treatment of Parkinson's disease, particularly in cases where dopamine-replacement approaches remain unsuccessful to satisfactorily combat the symptoms. (PD is the result of loss of dopamine-generating cells in the nigrostriatal system). (PRNewsFoto/StemGenex) (PRNewsFoto/STEMGENEX)
What is Parkinson's Disease? Parkinson's disease is a chronic progressive neurological disease that affects nerve cells (neurons) in an area of the brain known as the substantia nigra. When healthy these cells normally produce dopamine, a chemical (neurotransmitter) which transmits signals between areas in the brain. This chemical coordinates smooth and balanced muscle movement. Parkinson's disease causes these nerve cells to die, and as a result, body movements are affected. (PRNewsFoto/StemGenex) (PRNewsFoto/STEMGENEX)
What is Parkinson's Disease? Parkinson's disease is a chronic progressive neurological disease that affects nerve cells (neurons) in an area of the brain known as the substantia nigra. When healthy these cells normally produce dopamine, a chemical (neurotransmitter) which transmits signals between areas in the brain. This chemical coordinates smooth and balanced muscle movement. Parkinson's disease causes these nerve cells to die, and as a result, body movements are affected. (PRNewsFoto/StemGenex) (PRNewsFoto/STEMGENEX)

Fast forward to 2013, stem cells offer a window into brain degenerating Parkinson's disease (PD). Scientists have found stem cells to be especially promising for treating rapidly-progressing diseases. Current findings propose that stem cells are appropriate in the management of neurodegenerative disorders.

Adipose-derived adult stem (ADAS) cells are the multipotent cells and precursors for the important cells of the central nervous system. Researchers have found that these stem cells self-renew and provide a therapeutic effect by differentiating into dopaminergic neurons and expressing neurotrophic factors e.g. brain-derived neurotrophic factor (BDNF) and glial derived neurotrophic factor (GDNF). All these facilitate protection of the nigrostriatal system thus offering a revolutionary and new prospect for the treatment of Parkinson's disease, particularly in cases where existing dopamine-replacement approaches remain unsuccessful to satisfactorily combat the symptoms.  (PD is the result of loss of dopamine-generating cells in the nigrostriatal system).

Kitada M and Dezawa M, the two prominent researchers of Tohoku University Graduate School of Medicine, Sendai, Japan, noted that cell transplantation holds a great potential for treating Parkinson's disease, and numerous other diseases. According to them, the stem cells are easily accessible and are devoid of serious technical and ethical problems and are the appropriate candidates for transplantation.  Stem cell therapy is a unique way to repair or replace the damaged or dead cells in the disease process, and re-establish cell function and alleviate symptoms.  Thus, such cells may bring about improvement in clinical manifestations of neurodegenerative diseases and neural injuries.

StemGenex® a leading independent U.S. based company has observed researcher's findings to be accurate while working with patients diagnosed with Parkinson's disease. StemGenex provides access to promising treatment for Parkinson's disease via adipose-derived stem cells.  The majority of patients with PD who have undergone this therapy are progressively reporting a reduction of their symptoms and improvement of their quality of living.

StemGenex® is recognized for its service to health, including its function in laying the basis for innovative treatments for Parkinson's disease, Alzheimer's disease, Multiple Sclerosis, Autoimmune diseases, and COPD. It is determined on providing the therapeutic applications of stem cells. New studies and clinical trials are under consideration by the company for the human well-being and health.

To find out more information on adipose stem cell treatments for Parkinson's disease contact StemGenex at 800-609-7795.

[email protected]

http://www.StemGenex.com

Related Links:
Stem Cell Treatments 
Contact StemGenex

Video with caption: "Stem Cell Therapy - A Solution For Parkinson's Disease A Computer Graphic visualization of a Brain cell synapse showing chemical messengers or neurotransmitters released from pre-synaptic neuron to be received by the post-synaptic nerve cell receptor." Video available at:  http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/FX-MM02678-20131023-03.mp4 

Image with caption: "Adipose-derived adult stem (ADAS) cells are the multipotent cells and precursors for the important cells of the central nervous system. Researchers have found that these stem cells self-renew and provide a therapeutic effect by differentiating into dopaminergic neurons and expressing neurotrophic factors e.g. brain-derived neurotrophic factor (BDNF) and glial derived neurotrophic factor (GDNF). All these facilitate protection of the nigrostriatal system thus offering a revolutionary and new prospect for the treatment of Parkinson's disease, particularly in cases where dopamine-replacement approaches remain unsuccessful to satisfactorily combat the symptoms. (PD is the result of loss of dopamine-generating cells in the nigrostriatal system)." Image available at: http://photos.prnewswire.com/prnh/20131023/MM02678-a

Image with caption: "What is Parkinson's Disease? Parkinson's disease is a chronic progressive neurological disease that affects nerve cells (neurons) in an area of the brain known as the substantia nigra. When healthy these cells normally produce dopamine, a chemical (neurotransmitter) which transmits signals between areas in the brain. This chemical coordinates smooth and balanced muscle movement. Parkinson's disease causes these nerve cells to die, and as a result, body movements are affected." Image available at: http://photos.prnewswire.com/prnh/20131023/MM02678-b

SOURCE StemGenex

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.